Search is Powered by Google
Cancer / Oncology News

National Cancer Institute Again Awards Competitive Grant To Indiana University Melvin And Bren Simon Cancer Center

Main Category: Cancer / Oncology
Article Date: 08 Oct 2008 - 10:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:not yet rated

Health Professional:not yet rated

Article Opinions: 0 posts

The Indiana University Melvin and Bren Simon Cancer Center has been recognized as a premier cancer center for the third consecutive time by the National Cancer Institute.

Since 1999, the IU Simon Cancer Center has carried the prestigious NCI designation. This year, the NCI awarded the IU Simon Cancer Center a five-year, $6.5 million support grant following a multi-step competitive process.

The NCI designation places the IU Simon Cancer Center in an elite group of 64 research centers across the country that focus on the rapid translation of research discoveries to directly benefit people with cancer. It is the only NCI-designated cancer center in Indiana that provides patient care and performs basic research. (The Purdue Cancer Center is an NCI-designated cancer center that provides basic research only.)

"This recognition by the NCI was made possible by the efforts of scores of our members and associates," said Stephen D. Williams, M.D., director of the IU Simon Cancer Center and HH Gregg Professor of Oncology at the IU School of Medicine. "It stands as a testimony to the talented researchers and physicians here who conduct cutting-edge cancer research and translate these findings to patients and those at risk for cancer."

Linda Weiss, Ph.D., chief of the Cancer Centers Branch of the NCI, added, "NCI-designated cancer centers, such as the IU Simon Cancer Center, are focused on discovering more about what causes cancer, and linking those research discoveries to the development of new and better methods in cancer prevention, early detection, treatment, and support for cancer survivors and their families,"

In addition to providing seed money for new research, the NCI grant will support center leadership, research-related administrative functions, and shared research resources.

The IU Simon Cancer Center first received the NCI designation in 1999, just seven years after its founding. Centers must be reviewed every four to five years to determine if they continue to meet the strict criteria required of NCI clinical cancer centers.

Grant funding awarded to IU cancer researchers and membership has continued to grow since 1999. External funding has grown from $29.4 million in 1999 to $75 million today.

The membership of the IU Simon Cancer Center has grown from 150 members - researchers and oncologists -- in 1999 to its current 225 members.

Physicians and researchers at IU have been at the forefront of caring for cancer patients and developing new treatments that have become the standard of care worldwide. They have turned the cure rate of testicular cancer from 10 percent to nearly 95 percent today and gained an international recognition for treatment of breast, genitourinary, thoracic, hematologic and gastrointestinal cancers. IU Simon Cancer Center physicians at Riley Hospital for Children and Indiana University Hospital are recognized nationally for their bone marrow and stem cell transplantation program.

Members and collaborators of the cancer center are on the faculties of the IU schools of medicine, nursing, and dentistry as well as the science departments at IU and Purdue University.

Indiana University Melvin and Bren Simon Cancer Center
http://cancer.iu.edu




Customized Homepage Weekly Newsletters Daily News Alerts
Home About Us News Licensing Free Website Feeds Free Tools & Content Links Tell a Friend Accessibility Help / FAQ Article Submission Contact Us
Psychiatry Urology
Bipolar Diabetes Schizophrenia

customize your homepage

medical news gadget

Add to Google


developers
website gadget code
website news code
medical news rss feed links


MedReader RSS Reader

customize your homepage


Monitoring and Adherence in CML image Monitoring and Adherence in CML

Imatinib, or Gleevec, is a targeted anti-cancer drug that can keep chronic myelogenous leukemia (CML) in check for most patients for many years. It is important for patients to take imatinib as prescribed by their doctor to fight the disease and to guard against resistance...

Treating HER2+ Breast Cancer image Treating HER2+ Breast Cancer

There are at least four different kinds of breast cancer and each is treated differently. For HER2+ breast cancer, a chemotherapy drug is typically the best option. Here's an overview of the drugs used to treat breast cancer...

View more videos...